Miscellaneous urogenital disorders:
Indications for: TARPEYO
To reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
Adult Dosage:
Swallow whole. Take in the AM at least 1hr before a meal. 16mg once daily. Treat for 9 months. When discontinuing treatment, reduce dose to 8mg once daily for the last 2 weeks.
Children Dosage:
Not established.
TARPEYO Warnings/Precautions:
Avoid in active or quiescent tuberculosis, untreated fungal, bacterial, systemic viral or parasitic infections, or ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin or antiviral prophylactic therapies. Supplement with systemic corticosteroids in surgery or other stress situations. Monitor for adrenal axis suppression when discontinuing therapy or switching between corticosteroids. Hypertension. Diabetes. Osteoporosis. Peptic ulcer. Glaucoma. Cataracts. Moderate hepatic impairment: monitor for hypercorticism. Severe hepatic impairment: avoid. Elderly. Pregnancy. Nursing mothers.
TARPEYO Classification:
Glucocorticoid.
TARPEYO Interactions:
Avoid grapefruit juice. May be potentiated by potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, cyclosporine); avoid. May decrease immune response to some vaccines.
Adverse Reactions:
Hypertension, peripheral edema, muscle spasms, acne, dermatitis, weight increase, dyspnea, face edema, dyspepsia, fatigue, hirsutism; hypercorticism.
Generic Drug Availability:
NO
How Supplied:
Caps—120
